Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danielle A Griffin

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 13, 2017
Systemic AAV-Mediated β-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E MiceEric R Pozsgai, Danielle A Griffin, Kristin N Heller, et al.
Biology Open|September 6, 2023
Expression and function of four AAV-based constructs for dystrophin restoration in the mdx mouse model of Duchenne muscular dystrophyRachael A Potter, Danielle A Griffin, Kristin N Heller, et al.
Human Gene Therapy|December 22, 2020
Preclinical Systemic Delivery of Adeno-Associated α-Sarcoglycan Gene Transfer for Limb-Girdle Muscular DystrophyDanielle A Griffin, Eric R Pozsgai, Kristin N Heller, et al.
Human Gene Therapy|January 5, 2021
Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the <i>mdx</i> Mouse Model of Duchenne Muscular DystrophyRachael A Potter, Danielle A Griffin, Kristin N Heller, et al.
Therapeutic Advances in Neurological Disorders|January 30, 2023
Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophyNatalie L Goedeker, Sachi D Dharia, Danielle A Griffin, et al.
Molecular Therapy. Methods & Clinical Development|March 31, 2022
Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerationsJerry R Mendell, Anne M Connolly, Kelly J Lehman, et al.
Human Molecular Genetics|February 26, 2016
Defective membrane fusion and repair in Anoctamin5-deficient muscular dystrophyDanielle A Griffin, Ryan W Johnson, Jarred M Whitlock, et al.
Molecular Therapy. Methods & Clinical Development|February 2, 2018
Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHDLindsay M Wallace, Nizar Y Saad, Nettie K Pyne, et al.
Molecular Therapy. Methods & Clinical Development|February 23, 2023
Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse modelYoung-Eun Seo, Stephen H Baine, Amber N Kempton, et al.
Annals of Clinical and Translational Neurology|March 28, 2015
AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal ModelsPatricia C Sondergaard, Danielle A Griffin, Eric R Pozsgai, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 13, 2017
Systemic AAV-Mediated β-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E MiceEric R Pozsgai, Danielle A Griffin, Kristin N Heller, et al.
Biology Open|September 6, 2023
Expression and function of four AAV-based constructs for dystrophin restoration in the mdx mouse model of Duchenne muscular dystrophyRachael A Potter, Danielle A Griffin, Kristin N Heller, et al.
Human Gene Therapy|December 22, 2020
Preclinical Systemic Delivery of Adeno-Associated α-Sarcoglycan Gene Transfer for Limb-Girdle Muscular DystrophyDanielle A Griffin, Eric R Pozsgai, Kristin N Heller, et al.
Human Gene Therapy|January 5, 2021
Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the <i>mdx</i> Mouse Model of Duchenne Muscular DystrophyRachael A Potter, Danielle A Griffin, Kristin N Heller, et al.
Therapeutic Advances in Neurological Disorders|January 30, 2023
Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophyNatalie L Goedeker, Sachi D Dharia, Danielle A Griffin, et al.
Molecular Therapy. Methods & Clinical Development|March 31, 2022
Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerationsJerry R Mendell, Anne M Connolly, Kelly J Lehman, et al.
Human Molecular Genetics|February 26, 2016
Defective membrane fusion and repair in Anoctamin5-deficient muscular dystrophyDanielle A Griffin, Ryan W Johnson, Jarred M Whitlock, et al.
Molecular Therapy. Methods & Clinical Development|February 2, 2018
Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHDLindsay M Wallace, Nizar Y Saad, Nettie K Pyne, et al.
Molecular Therapy. Methods & Clinical Development|February 23, 2023
Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse modelYoung-Eun Seo, Stephen H Baine, Amber N Kempton, et al.
Annals of Clinical and Translational Neurology|March 28, 2015
AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal ModelsPatricia C Sondergaard, Danielle A Griffin, Eric R Pozsgai, et al.
Pageof 2